[Poinsettia: A wholly-owned subsidiary has obtained the registration certificate for compound polyethylene glycol electrolyte oral solution] On September 20, Poinsettia (300723.SZ) announced that the company’s wholly-owned subsidiary Guangzhou Poinsettia Pharmaceutical recently received a national drug The Compound Polyethylene Glycol (3350) Electrolyte Oral Solution "Drug Registration Certificate" approved and issued by the Supervision Bureau. The drug registration is classified as Class 3 chemical drugs and is deemed to have passed the consistency evaluation. The indications are the treatment of chronic constipation and fecal impaction. According to data from Minai.com, the sales volume of polyethylene glycol in China's urban and county-level public hospitals in 2025 will be approximately 221 million yuan. This approval marks that the company is qualified to sell the drug in the domestic market, which will further enrich the product pipeline and enhance the competitiveness of chronic disease drugs.